Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2020

Open Access 01-12-2020 | Chronic Obstructive Lung Disease | Study protocol

REALizing and improving management of stable COPD in China: a multi-center, prospective, observational study to realize the current situation of COPD patients in China (REAL) – rationale, study design, and protocol

Authors: Ting Yang, Baiqiang Cai, Bin Cao, Jian Kang, Fuqiang Wen, Wanzhen Yao, Jinping Zheng, Xia Ling, Hongyan Shang, Chen Wang

Published in: BMC Pulmonary Medicine | Issue 1/2020

Login to get access

Abstract

Background

Chronic obstructive pulmonary disease (COPD) is the fifth leading cause of death in China with a reported prevalence of 8.2% people aged ≥40 years. It is recommended that Chinese physicians follow Global Initiative for Chronic Obstructive Lung Disease (GOLD) and national guidelines, yet many patients with COPD in China remain undiagnosed. Furthermore, missed diagnoses and a lack of standardized diagnosis and treatment remain significant problems. The situation is further complicated by a lack of large-scale, long-term, prospective studies of real-world outcomes, including exacerbation rates, disease severity, efficacy of treatment, and compliance of COPD patients in China.

Methods/design

The REALizing and improving management of stable COPD in China (REAL) study is a 52-week multi-center, prospective, observational trial. REAL aims to recruit approximately 5000 outpatients aged ≥40 years with a clinical diagnosis of COPD per GOLD 2016. Outpatients will be consecutively recruited from approximately 50 tertiary and secondary hospitals randomly selected across six geographic regions to provide a representative population. Patients will receive conventional medical care as determined by their treating physicians.
The primary objective is to evaluate COPD patient outcomes including lung function, health status, exacerbations, hospitalization rate, and dyspnea following 1 year of current clinical practice. Secondary objectives are to assess disease severity, treatment patterns, adherence to medication, and associated risk factors. Data will be collected at two study visits, at patients’ usual care visits, and by telephone interview every 3 months.

Discussion

Knowledge of COPD among physicians in China is poor. The REAL study will provide reliable information on COPD management, outcomes, and risk factors that may help improve the standard of care in China. Patient recruitment began on 30 June 2017 and the estimated primary completion date is 30 July 2019.

Trial registration

ClinicalTrials.gov identifier: NCT03131362. Registered on 20 March 2017.
Appendix
Available only for authorised users
Literature
1.
go back to reference GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease report. 2017. http://goldcopd.org/. Accessed 02 Oct 2017. GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease report. 2017. http://​goldcopd.​org/​. Accessed 02 Oct 2017.
2.
go back to reference GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–544.CrossRef GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–544.CrossRef
3.
go back to reference Fang X, Wang X, Bai C. COPD in China: the burden and importance of proper management. Chest. 2011;139:920–9.PubMedCrossRef Fang X, Wang X, Bai C. COPD in China: the burden and importance of proper management. Chest. 2011;139:920–9.PubMedCrossRef
4.
go back to reference Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176:753–60.PubMedCrossRef Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176:753–60.PubMedCrossRef
5.
go back to reference Chinese Society of Respiratory Disease. The guideline for the diagnosis and treatment of chronic obstructive pulmonary disease (2013 revision). Zhonghua Jie He He Hu Xi Za Zhi. 2013;36:255–64. Chinese Society of Respiratory Disease. The guideline for the diagnosis and treatment of chronic obstructive pulmonary disease (2013 revision). Zhonghua Jie He He Hu Xi Za Zhi. 2013;36:255–64.
6.
go back to reference GOLD. Global Strategy For The Diagnosis, Management, And Prevention Of Chronic Obstructive Pulmonary Disease Report. 2011. Available upon request from http://goldcopd.org/. Accessed 02 Oct 2017. GOLD. Global Strategy For The Diagnosis, Management, And Prevention Of Chronic Obstructive Pulmonary Disease Report. 2011. Available upon request from http://​goldcopd.​org/​. Accessed 02 Oct 2017.
7.
go back to reference Fang X, Li S, Gao L, Zhao N, Wang X, Bai C. A short-term educational program improved physicians’ adherence to guidelines for COPD and asthma in Shanghai. Clin Transl Med. 2012;1:13.PubMedPubMedCentralCrossRef Fang X, Li S, Gao L, Zhao N, Wang X, Bai C. A short-term educational program improved physicians’ adherence to guidelines for COPD and asthma in Shanghai. Clin Transl Med. 2012;1:13.PubMedPubMedCentralCrossRef
8.
go back to reference Zhou XM, Wu C, Zhao L, Gao YZ, Yuan Y, Xiao XX, et al. A cross-sectional survey of the knowledge on chronic obstructive pulmonary disease in physicians of tertiary hospitals in northern China. Zhonghua Nei Ke Za Zhi. 2016;55:717–20.PubMed Zhou XM, Wu C, Zhao L, Gao YZ, Yuan Y, Xiao XX, et al. A cross-sectional survey of the knowledge on chronic obstructive pulmonary disease in physicians of tertiary hospitals in northern China. Zhonghua Nei Ke Za Zhi. 2016;55:717–20.PubMed
9.
go back to reference Liu S, Zhou Y, Wang X, Wang D, Lu J, Zheng J, et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. Thorax. 2007;62:889–97.PubMedPubMedCentralCrossRef Liu S, Zhou Y, Wang X, Wang D, Lu J, Zheng J, et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. Thorax. 2007;62:889–97.PubMedPubMedCentralCrossRef
10.
go back to reference Han R, Zou J, Shen X, Wu C, Guo Y, Feng Z, et al. The risk factors of chronic obstructive pulmonary disease in Heilongjiang province. Zhonghua Jie He He Hu Xi Za Zhi. 2015;38:93–8.PubMed Han R, Zou J, Shen X, Wu C, Guo Y, Feng Z, et al. The risk factors of chronic obstructive pulmonary disease in Heilongjiang province. Zhonghua Jie He He Hu Xi Za Zhi. 2015;38:93–8.PubMed
11.
go back to reference Cho S, Lin H, Ghoshal AG, Bin AM, Thanaviratananich S, Bagga S, et al. Respiratory disease in the Asia-Pacific region: cough as a key symptom. Allergy Asthma Proc. 2016;37:131–40.PubMedCrossRef Cho S, Lin H, Ghoshal AG, Bin AM, Thanaviratananich S, Bagga S, et al. Respiratory disease in the Asia-Pacific region: cough as a key symptom. Allergy Asthma Proc. 2016;37:131–40.PubMedCrossRef
12.
go back to reference Lin H, Cho S, Ghoshal AG, Muttalif ARBA, Thanaviratananich S, Bagga S, et al. Respiratory diseases and the impact of cough in Taiwan: results from the APBORD observational study. Medicine. 2016;95:e3854.PubMedPubMedCentralCrossRef Lin H, Cho S, Ghoshal AG, Muttalif ARBA, Thanaviratananich S, Bagga S, et al. Respiratory diseases and the impact of cough in Taiwan: results from the APBORD observational study. Medicine. 2016;95:e3854.PubMedPubMedCentralCrossRef
13.
go back to reference Xiao T, Chen XY, Wang N, Zhao Q, Fu CW, Xu B. Study on the situation of drug use in patients with chronic obstructive pulmonary diseases in the Chinese communities of large cities. Zhonghua Liu Xing Bing Xue Za Zhi. 2017;38:142–6.PubMed Xiao T, Chen XY, Wang N, Zhao Q, Fu CW, Xu B. Study on the situation of drug use in patients with chronic obstructive pulmonary diseases in the Chinese communities of large cities. Zhonghua Liu Xing Bing Xue Za Zhi. 2017;38:142–6.PubMed
14.
go back to reference Jones PW, Harding G, Berry P, Wiklund I, Chen W, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34:648–54.PubMedCrossRef Jones PW, Harding G, Berry P, Wiklund I, Chen W, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34:648–54.PubMedCrossRef
15.
go back to reference Fletcher CM. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of chronic bronchitis (MRC breathlessness score). Br Med J. 1960;2:1662. Fletcher CM. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of chronic bronchitis (MRC breathlessness score). Br Med J. 1960;2:1662.
16.
go back to reference Maples P, Franks A, Ray S, Stevens AB, Wallace LS. Development and validation of a low-literacy chronic obstructive pulmonary disease knowledge questionnaire (COPD-Q). Patient Educ Couns. 2010;81:19–22.PubMedCrossRef Maples P, Franks A, Ray S, Stevens AB, Wallace LS. Development and validation of a low-literacy chronic obstructive pulmonary disease knowledge questionnaire (COPD-Q). Patient Educ Couns. 2010;81:19–22.PubMedCrossRef
18.
go back to reference Chan A, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–7.PubMedPubMedCentralCrossRef Chan A, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–7.PubMedPubMedCentralCrossRef
19.
go back to reference Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204.PubMedCrossRef Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204.PubMedCrossRef
20.
go back to reference He Q, Zhou X, Xie CM, et al. The importance of health education and management on the diagnosis and treatment for COPD. Chin J Prev Contr Chron Dis. 2009;17:441–3. He Q, Zhou X, Xie CM, et al. The importance of health education and management on the diagnosis and treatment for COPD. Chin J Prev Contr Chron Dis. 2009;17:441–3.
21.
go back to reference Chen Y, Yao W, Kang J, Cai B, Zhou X, Liu Z, et al. Attitudes and actions of chronic obstructive pulmonary disease patients on treatment: a national multi-center investigative study. Zhonghua Jie He He Hu Xi Za Zhi. 2010;33:750–3.PubMed Chen Y, Yao W, Kang J, Cai B, Zhou X, Liu Z, et al. Attitudes and actions of chronic obstructive pulmonary disease patients on treatment: a national multi-center investigative study. Zhonghua Jie He He Hu Xi Za Zhi. 2010;33:750–3.PubMed
23.
go back to reference Yin P, Jiang CQ, Cheng KK, Lam TH, Lam KH, Miller MR, et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou biobank cohort study. Lancet. 2007;370:751–7.PubMedCrossRef Yin P, Jiang CQ, Cheng KK, Lam TH, Lam KH, Miller MR, et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou biobank cohort study. Lancet. 2007;370:751–7.PubMedCrossRef
24.
go back to reference Shen N, He B. Is the new GOLD classification applicable in China? Lancet Glob Health. 2013;1:e247–8.PubMedCrossRef Shen N, He B. Is the new GOLD classification applicable in China? Lancet Glob Health. 2013;1:e247–8.PubMedCrossRef
25.
go back to reference He W, Zhao Q, Ye R, Wei J. A preliminary investigation of pulmonary function in the diagnosis of chronic obstructive pulmonary disease in some provinces and cities in China. Zhonghua Jie He He Hu Xi Za Zhi. 2003;26:39–40. He W, Zhao Q, Ye R, Wei J. A preliminary investigation of pulmonary function in the diagnosis of chronic obstructive pulmonary disease in some provinces and cities in China. Zhonghua Jie He He Hu Xi Za Zhi. 2003;26:39–40.
26.
go back to reference Shen N, Yao W, Zhu H. Patient’ s perspective of chronic obstructive pulmonary disease in Yanqing county of Beijing. Zhonghua Jie He He Hu Xi Za Zhi. 2008;31:206–8.PubMed Shen N, Yao W, Zhu H. Patient’ s perspective of chronic obstructive pulmonary disease in Yanqing county of Beijing. Zhonghua Jie He He Hu Xi Za Zhi. 2008;31:206–8.PubMed
27.
go back to reference Chan HP, Mukhopadhyay A, Chong PLP, Chin S, Wong XY, Ong V, et al. Prognostic utility of the 2011 GOLD classification and other multidimensional tools in Asian COPD patients: a prospective cohort study. Int J Chron Obstruct Pulmon Dis. 2016;11:823–9.PubMedPubMedCentralCrossRef Chan HP, Mukhopadhyay A, Chong PLP, Chin S, Wong XY, Ong V, et al. Prognostic utility of the 2011 GOLD classification and other multidimensional tools in Asian COPD patients: a prospective cohort study. Int J Chron Obstruct Pulmon Dis. 2016;11:823–9.PubMedPubMedCentralCrossRef
29.
go back to reference Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581–6.PubMedPubMedCentralCrossRef Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581–6.PubMedPubMedCentralCrossRef
30.
go back to reference Karloh M, Fleig Mayer A, Maurici R, Pizzichini MMM, Jones PW, Pizzichini E. The COPD assessment test: what do we know so far?: a systematic review and meta-analysis about clinical outcomes prediction and classification of patients into GOLD stages. Chest. 2016;149:413–25.PubMedCrossRef Karloh M, Fleig Mayer A, Maurici R, Pizzichini MMM, Jones PW, Pizzichini E. The COPD assessment test: what do we know so far?: a systematic review and meta-analysis about clinical outcomes prediction and classification of patients into GOLD stages. Chest. 2016;149:413–25.PubMedCrossRef
31.
go back to reference Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's respiratory questionnaire. Am Rev Respir Dis. 1992;145:1321–7.PubMedCrossRef Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's respiratory questionnaire. Am Rev Respir Dis. 1992;145:1321–7.PubMedCrossRef
32.
go back to reference Agustí A, Soler JJ, Molina J, Muñoz MJ, García-Losa M, Roset M, et al. Is the CAT questionnaire sensitive to changes in health status in patients with severe COPD exacerbations? COPD. 2012;9:492–8.PubMedCrossRef Agustí A, Soler JJ, Molina J, Muñoz MJ, García-Losa M, Roset M, et al. Is the CAT questionnaire sensitive to changes in health status in patients with severe COPD exacerbations? COPD. 2012;9:492–8.PubMedCrossRef
33.
go back to reference Zhou Q, Mei J, He B, Huang S, Shi Y, Wen F, et al. Chronic obstructive pulmonary disease assessment test score correlated with dyspnea score in a large sample of Chinese patients. Chin Med J. 2013;126:11–5.PubMed Zhou Q, Mei J, He B, Huang S, Shi Y, Wen F, et al. Chronic obstructive pulmonary disease assessment test score correlated with dyspnea score in a large sample of Chinese patients. Chin Med J. 2013;126:11–5.PubMed
34.
go back to reference Ray SM, Helmer RS, Stevens AB, Franks AS, Wallace LS. Clinical utility of the chronic obstructive pulmonary disease knowledge questionnaire. Fam Med. 2013;45:197–200.PubMed Ray SM, Helmer RS, Stevens AB, Franks AS, Wallace LS. Clinical utility of the chronic obstructive pulmonary disease knowledge questionnaire. Fam Med. 2013;45:197–200.PubMed
35.
go back to reference Puente-Maestu L, Chancafe-Morgan J, Calle M, Rodríguez-Hermosa JL, Malo DM, Ortega-González Á, et al. Validation of the Spanish version of the COPD-Q questionnaire on COPD knowledge. Arch Bronconeumol. 2016;52:12–6.PubMedCrossRef Puente-Maestu L, Chancafe-Morgan J, Calle M, Rodríguez-Hermosa JL, Malo DM, Ortega-González Á, et al. Validation of the Spanish version of the COPD-Q questionnaire on COPD knowledge. Arch Bronconeumol. 2016;52:12–6.PubMedCrossRef
36.
go back to reference Ye Y, Zhu B, Jiang L, Jiang Q, Wang M, Hua L, et al. A contemporary assessment of acute mechanical ventilation in Beijing: description, costs, and outcomes. Crit Care Med. 2017;45:1160–7.PubMedPubMedCentralCrossRef Ye Y, Zhu B, Jiang L, Jiang Q, Wang M, Hua L, et al. A contemporary assessment of acute mechanical ventilation in Beijing: description, costs, and outcomes. Crit Care Med. 2017;45:1160–7.PubMedPubMedCentralCrossRef
37.
go back to reference Qiu YP, Zhao K, Li X, Shi LW, Guo WD, Qi XR, et al. Health economic evaluation of a 23 value pneumococcal polysaccharide vaccination pilot programme among elderly chronic obstructive pulmonary disease patients in China. Zhonghua Yu Fang Yi Xue Za Zhi. 2016;50:1074–8.PubMed Qiu YP, Zhao K, Li X, Shi LW, Guo WD, Qi XR, et al. Health economic evaluation of a 23 value pneumococcal polysaccharide vaccination pilot programme among elderly chronic obstructive pulmonary disease patients in China. Zhonghua Yu Fang Yi Xue Za Zhi. 2016;50:1074–8.PubMed
38.
go back to reference Song C, He J, Wu L, Jin T, Chen X, Li R, et al. Health burden attributable to ambient PM2.5 in China. Environ Pollut. 2017;223:575–86.PubMedCrossRef Song C, He J, Wu L, Jin T, Chen X, Li R, et al. Health burden attributable to ambient PM2.5 in China. Environ Pollut. 2017;223:575–86.PubMedCrossRef
39.
go back to reference Maji KJ, Arora M, Dikshit AK. Burden of disease attributed to ambient PM2.5 and PM10 exposure in 190 cities in China. Environ Sci Pollut Res Int. 2017;24:11559–72.PubMedCrossRef Maji KJ, Arora M, Dikshit AK. Burden of disease attributed to ambient PM2.5 and PM10 exposure in 190 cities in China. Environ Sci Pollut Res Int. 2017;24:11559–72.PubMedCrossRef
40.
go back to reference Wu M, Zhao Q, Chen Y, Fu C, Xu B. Quality of life and its association with direct medical costs for COPD in urban China. Health Qual Life Outcomes. 2015;13:57.PubMedPubMedCentralCrossRef Wu M, Zhao Q, Chen Y, Fu C, Xu B. Quality of life and its association with direct medical costs for COPD in urban China. Health Qual Life Outcomes. 2015;13:57.PubMedPubMedCentralCrossRef
41.
go back to reference Chen X, Wang N, Chen Y, Xiao T, Fu C, Xu B. Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities. Int J Chron Obstruct Pulmon Dis. 2016;11:2625–32.PubMedPubMedCentralCrossRef Chen X, Wang N, Chen Y, Xiao T, Fu C, Xu B. Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities. Int J Chron Obstruct Pulmon Dis. 2016;11:2625–32.PubMedPubMedCentralCrossRef
42.
go back to reference Ding B, Small M, Bergström G, Holmgren U. COPD symptom burden: impact on health care resource utilization, and work and activity impairment. Int J Chron Obstruct Pulmon Dis. 2017;12:677–89.PubMedPubMedCentralCrossRef Ding B, Small M, Bergström G, Holmgren U. COPD symptom burden: impact on health care resource utilization, and work and activity impairment. Int J Chron Obstruct Pulmon Dis. 2017;12:677–89.PubMedPubMedCentralCrossRef
43.
go back to reference Cao G, Li J, Li L, Li H, Wang F, Wang H, et al. Use of nonprescription medicines by patients with COPD: a survey in Chongqing municipality, China. Chron Respir Dis. 2012;9:77–81.PubMedCrossRef Cao G, Li J, Li L, Li H, Wang F, Wang H, et al. Use of nonprescription medicines by patients with COPD: a survey in Chongqing municipality, China. Chron Respir Dis. 2012;9:77–81.PubMedCrossRef
44.
go back to reference Wilkinson TMA, Donaldson GC, Hurst JR, Seemungal TAR, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169:1298–303.PubMedCrossRef Wilkinson TMA, Donaldson GC, Hurst JR, Seemungal TAR, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169:1298–303.PubMedCrossRef
Metadata
Title
REALizing and improving management of stable COPD in China: a multi-center, prospective, observational study to realize the current situation of COPD patients in China (REAL) – rationale, study design, and protocol
Authors
Ting Yang
Baiqiang Cai
Bin Cao
Jian Kang
Fuqiang Wen
Wanzhen Yao
Jinping Zheng
Xia Ling
Hongyan Shang
Chen Wang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2020
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-019-1000-x

Other articles of this Issue 1/2020

BMC Pulmonary Medicine 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.